Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Coronavirus disease 2019 (COVID-19) associated coagulopathy and its impact on outcomes in Shenzhen, China: A retrospective cohort study

Ying-yi Luan, Yan Liu, Xue-yan Liu, Bao-jun Yu, Rong-ling Chen, Mian Peng, Di Ren, Hao-li Li, Lei Huang, Yong Liu, Jin-xiu Li, Yong-wen Feng, Ming Wu

ABSTRACT

Background: Early detection of suspected critical patients infected with coronavirus disease 2019 (COVID-19) is very important for the treatment of patients. This study aimed to investigate the role of COVID-19 associated coagulopathy (CAC) to preview and triage. Methods and Results: A cohort study was designed from government designated COVID-19 treatment center. CAC was defined as International Society on Thrombosis and Haemostasis (ISTH) score ≥ 2. Data from 117 patients COVID-19 were reviewed on admission. The primary and secondary outcomes were admission to Intensive Care Unit (ICU), the use of mechanical ventilation, vital organ dysfunction, discharges of days 14, 21 and 28 from admission and hospital mortality. Among them, admission to ICU was increased progressively from 16.1% in patients with non-CAC to 42.6% in patients with CAC (P < 0.01). Likely, invasive ventilation and noninvasive ventilation were increased from 1.8% to 21.4% in patients with non-CAC to 21.3% in patients with CAC, respectively (P < 0.01). The incidences of acute hepatic injury and acute respiratory distress syndrome in non-CAC and CAC were 28.6% vs. 62.3%, 8.9% vs. 27.9%, respectively (P < 0.01). The discharges of days 14, 21 and 28 from admission were more in non-CAC than those of CAC (P < 0.05). Multiple logistic regression results showed that ISTH score ≥ 2 was obviously associated with the admission to ICU (OR 4.07, 95% CI 1.47–11.25 P = 0.007) and the use of mechanical ventilation (OR 5.54, 95% CI 2.01–15.28 P = 0.001) in patients with COVID-19. Conclusion: All results show ISTH score ≥ 2 is an important indicator to preview and triage for COVID-19 patients.

1. Introduction

The COVID-19 has features typical of the coronavirus family and is classified in the beta coronavirus 2β lineage [1,2]. Clinical classification of COVID-19 is mainly divided into light, common, severe, and critical types [3]. How to identify the patients who may become severe on the day of admission plays an important role in clinical triage treatment. For patients with bacterial sepsis, the early recognition of quick sepsis-related organ failure assessment (qSOFA) score is often used in clinic, but the respiratory rate in the early patients with COVID-19 is usually < 22 times/min, and the blood pressure is basically within normal range, thus it is difficult to identify early patients with qSOFA score.

Early detection of suspected severe patients infected with SARS-CoV-2 is very important for the treatment of patients. As we known, patients have been identified according to their respiratory rates, blood oxygen saturation or PO2/FiO2, which might delay their treatments and even increase the mortality to some extent at the early stage. Therefore, it is of great significance to further elucidate the pathophysiological mechanisms, and to seek the early indicators to estimate
the severity of the patients with COVID-19. It has been generally ac-
cepted that during pathogenic microorganism infection, host immunity,
flammation, coagulation are critically involved in the development of
septic complications. The results of clinical study showed that some
COVID-19 could cause coagulation abnormality and progressive ag-
gravation at the later stage, but disseminated intravascular coagulation
(DIC) was rare in those cases [2–4].

In order to determine the abnormal coagulation at the early stage,
coagulation markers, including thrombin-antithrombin complex (TAT),
α2-plasmininhibitor- plasmin complex (PIC), soluble thrombomodulin
(sTM), and tissue plasminogen activator-inhibitor complex (tPAIC) are
used to evaluate pre-DIC clinically. However, it is difficult to detect
these coagulation markers in the fever clinic when patients are novel
coronavirus nucleic acid positive. For evaluation of coagulation func-
tion, clinicians usually carry out five coagulation and platelet count
tests for patients. Using these indicators related to coagulation may
provide a reference for early detection of coagulopathy. Persistent
cogulopathy is associated with poor outcomes. Thus, this study was
based on coagulation monitoring indicators, using International Society
on Thrombosis and Haemostasis (ISTH) interim guidance to recognition
and management of coagulopathy in COVID-19, which might be able to
identify patients with coagulation activation and estimate the severity
of patients [5].

As the most consistent hemostatic abnormalities with COVID-19
include mild thrombocytopenia and increased D-dimer levels, > 70% of
COVID-19 patients who died fulfilled the ISTH score ≥ 5 points, com-
pared with only 0.6% among survivors [6]. This means that COVID-19-
related DIC is rare in surviving patients especially in the early stages of
COVID-19. In the present study, COVID-19 patient cohort was admitted
by ISTH score and its scores between 0 and 3 points from January 14,
2020 to February 11, 2020. Thus, the COVID-19 patients were divided
into non-COVID-19 associated coagulopathy (CAC) and CAC groups
according to the ISTH score (2 points), then the clinical characteristics,
admission to intensive care unit (ICU), the use of mechanical ventila-
tion, the vital organ dysfunction, and discharges of 14 days, 21 days
and 28 days from admission as well as hospital mortality were com-
pared between two groups in our study.

2. Methods

2.1. Study design, setting and participants

This retrospective cohort study was designed by the investigators
and performed at the Third People’s Hospital of Shenzhen between
January 14, 2020 and February 11, 2020. The data cutoff for the study
was March 20, 2020. Written informed consent was waived in light of
the urgent need to collect data. Data were obtained from 149 patients
with COVID-19 hospitalized at Department of Critical Care Medicine
and Infection Third Ward during the study dates. A confirmed case of
COVID-19 was defined as a positive result on real-time reverse-tran-
scriptase–polymerase-chain-reaction (RT-PCR) assay of pharyngeal
swab specimens by Shenzhen center for disease prevention and control
(CDC). The discharges criterion was negative two times 24 hour
interval result on RT-PCR assay of pharyngeal swab specimens by
Shenzhen CDC. The study analyzed de-identified data from the hospi-
tal’s healthcare informatics group, which was supervised by Shenzhen
Municipal Health Commission. The study protocol was approved by the
Second People’s Hospital of Shenzhen & First Affiliated Hospital of
Shenzhen University (institutional review board [IRB] number
202003009004).

2.2. Data collection and definitions

All routinely collected vital signs and symptoms and laboratory
values were extracted from the electronic health records. Data included,
but were not limited to, demographic data (e.g. age, gender, body mass
index [BMI]), biochemical parameters (e.g. blood cell count, liver
function, kidney function, coagulation function, blood gas analysis),
mechanic ventilation and comorbidities including hypertension, dia-
abetes, cerebrovascular disease, chronic obstructive pulmonary disease
(COPD), and malignancy for severity of illness. We calculated the Acute
Physiology and Chronic Health Evaluation (APACHE) II score within
first 24 h of hospitalization.

Shock and acute respiratory distress syndrome (ARDS) were defined
in accordance with the WHO interim guidance [7]. Acute kidney injury
was defined based on Kidney Disease: Improving Global Outcomes
Clinical Practice Guidelines (KDIGO) [8]. Acute cardiac dysfunction
was defined as the clinical syndrome characterized by typical symptoms
(e.g. breathlessness, fatigue, and ankle swelling) that may be accom-
panied by signs (e.g. elevated jugular venous pressure, and pulmonary
crackles) caused by cardiac abnormality. Acute hepatic injury was de-
finite as a state in which the patient’s blood laboratory results met at
least one of three criteria: serum total bilirubin (TBil) of 3.0 mg/dL or
greater; aspartate aminotransferase (AST) of 41 IU/L or greater; alanine
aminotransferase (ALT) of 41 IU/L or greater; The patients who met
none of these criteria were classified as the “normal liver function”
group [9].

2.3. Main measures and outcomes

CAC was defined as ISTH score more than or equal to 2 points. The
primary end points were admission to an ICU and the use of mechanical
ventilation. The secondary end points were vital organ function, and
discharges of 14 days, 21 days and 28 days from admission as well as
hospital mortality.

2.4. Statistical analysis

The categorical data were summarized as numbers and percentages,
and χ2 tests or Fisher’s exact test to compare between CAC and non-
CAC groups. Continuous variables were expressed as the arithmetic
mean and standard deviation (SD) or as the median and interquartile
range, depending on whether or not they showed a Gaussian distribu-
tion. Continuous data with Gaussian distribution were compared with
the Student’s t-test and those with a non-Gaussian distribution, with the
Wilcoxon rank-sum test. Univariable and multivariable logistic regression
analysis with odds ratio (OR) and 95% confidence interval levels
(95% CI) were performed to evaluate risk factors associated with ad-
mision to ICU and mechanical ventilation. The following variables
were investigated as independent risk factors for mechanical ventila-
tion: comorbid conditions, age, gender, platelet count, neutrophil
lymphocyte ratio, alanine aminotransferase, aspartate transaminase,
creatinine, ISTH score, and APACH II score. The same variables plus
creatinine were investigated as risk factors for admission to ICU.
Statistical analysis was performed using the statistical package SAS 9.4
(Windows, SAS Institute, Cary, North Carolina). P values (two-tailed)
below 0.05 were considered statistically significant.

3. Results

3.1. Demographics and baseline characteristics

The detailed demographic and clinical profile data of all patients
with COVID-19 on admission baseline were summarized in Table 1. By
February 11, 2020, clinical data were collected in 149 patients in the
Department of Critical Care Medicine and Infection Third Ward with
laboratory confirmed COVID-19 (Fig. 1). There were 5 patients without
D-Dimer, 8 patients without platelets, 17 patients without prothrombin
time, fibrinogen, D-Dimer and 2 patients without platelets, pro-
thrombin time, fibrinogen and D-Dimer on admission. A total of 117
patients were enrolled in this study finally (52 males, 53%). Patient’s
mean age was 61.9 years. 104 (88.9%) patients had a history of
exposure to the Hubei or the individuals with confirmed COVID-19. Of these patients, the mean body mass index (BMI) was 23.9, body temperature was 37.5 °C, respiration rate was 20.5 times/min, mean arterial pressure (MAP) was 97.3 mm Hg. The APACHE II was between 2 to 7 points and the ISTH score was between 0 to 3 points, the distribution of ISTH scores in Fig. 2. This patients with ISTH ≥ 2 points had more comorbidities than that of ISTH < 2 points (41.0% vs. 17.9%, P = 0.006).

In terms of signs and symptoms, there were no significant differences between the two groups. A patient's Glasgow coma scale (GCS) was ≥ 3 in the CAC group and the other was 15 points (P = 0.32). Notably, APACHE II score was significantly higher in the CAC group compared to the non-CAC group (CAC 9.5 [4.6, 17.0] vs. non-CAC 9.5 [4.0, 6.0], P = 0.022).

3.2. Laboratory findings and CAC score on admission

There were significant differences in levels of procalcitonin (PCT), C-reactive protein (CRP), interleukin 6 (IL-6), neutrophil, lymphocyte, neutrophil to lymphocyte ratio (NLR), albumin, alanine aminotransferase, aspartate aminotransferase, pH, PO2, PO2/FiO2, D-dimer, and fibrinogen between the CAC and non-CAC groups (Table 2). Inflammatory indexes including PCT, CRP, and IL-6 were higher in patients with CAC (P < 0.05). In comparison to the non-CAC group, lymphocyte counts were lower, and neutrophils as well as NLR were increased in the CAC group (P < 0.01), showing that NLR in CAC patients was 3.2. D-dimer and fibrinogen levels, and ISTH scores in patients with CAC were higher than those of non-CAC patients (P < 0.01).

3.3. Complications and outcomes of patients with COVID-19

There were significant differences in the proportions of admission to ICU, the use of invasive ventilation and noninvasive ventilation, acute hepatic injury, and acute lung injury as well as discharges of 14 days, 21 days and 28 days from admission. There were no significant differences in incidences in shock, acute cardiac insufficiency, and acute renal injury (P > 0.05) (Table 3). Other main clinical outcomes, such as the proportion of admission to ICU (16.1% vs. 42.6%), acute hepatic injury (28.6% vs. 62.3%) and ARDS (8.9% vs. 27.9%), and invasive ventilation (1.8% vs. 21.3%) as well as noninvasive ventilation (21.4% vs. 52.5%) were increased in the non-CAC group than those of the CAC group (all P < 0.01). The discharges of 14 days, 21 days and 28 days from admission were 48.2% vs. 16.4%, 75.0% vs. 45.9%, 89.3% vs. 52.5%) were increased in the non-CAC group than those of the CAC group (all P < 0.01). The discharges of 14 days, 21 days and 28 days from admission were 48.2% vs. 16.4%, 75.0% vs. 45.9%, 89.3% vs. 52.5%) were increased in the non-CAC group than those of the CAC group (all P < 0.01). The discharges of 14 days, 21 days and 28 days from admission were 48.2% vs. 16.4%, 75.0% vs. 45.9%, 89.3% vs. 52.5%) were increased in the non-CAC group than those of the CAC group (all P < 0.01).
male, BMI, platelet count, NLR, alanine aminotransferase, aspartate transaminase, and creatinine as variables from demographic data, biochemical parameters, and the others were comorbidities, ISTH scores, and APACHE II scores.

Multiple logistic regression results showed that only age > 60 (OR 5.12, 95% CI 1.96–13.89, P = 0.001), male (OR 6.47, 95% CI 2.22–18.91, P < 0.001), and ISTH score ≥ 2 (OR, 4.07, 95% CI 1.47–11.25 P = 0.007) were obviously associated with the admission to ICU in patient with COVID-19 (Table 4).

Multiple logistic regression results revealed that only age > 60 (OR 4.94, 95% CI 1.84–13.27, P = 0.0020), male (OR 8.43, 95% CI 2.86–24.85, P < 0.001), and ISTH score ≥ 2 (OR 5.54, 95% CI 2.01–15.28 P = 0.001) were significantly associated with the use of mechanical ventilation in patients with COVID-19 (Table 5).

4. Discussion

Our study showed that the admission to ICU was increased progressively from 16.1% in patients with non-CAC to 42.6% in patients with CAC with COVID-19. The incidence of invasive ventilation and noninvasive ventilation, acute hepatic injury and acute respiratory distress syndrome were high in CAC than that of non-CAC group. The results showed that ISTH score ≥ 2 was obviously associated with the admission to ICU (OR 4.07, 95% CI 1.47–11.25 P = 0.007) and the use of mechanical ventilation (OR 5.54, 95% CI 2.01–15.28 P = 0.001) in patients with COVID-19. All results show ISTH score ≥ 2 is an important indicator to preview and triage for COVID-19 patients when epidemic outbreak.

COVID-19 is a systemic multi-organ injury disease caused by severe acute respiratory syndrome (SARS)-CoV-2. Similar to that of SARS [10] and Middle East respiratory syndrome (MERS) [11], it involves many basic pathological processes, such as host immune, inflammation and coagulation. Over activation of immune cells, cytokine storm and excessive oxidative stress may be the common pathophysiological mechanism(s) underlying ARDS, septic shock, multiple organ failure, and even death caused by COVID-19, SARS, and MERS [12-15]. Critical COVID-19 characterized by refractory hypoxemia increases patient mortality because of dysregulation of host immune response. Studies showed that COVID-19 patients with severe ARDS have microthrombus [16]. The authors suggest that coagulation disorders may be involved in the pathological process of patients with critical COVID-19.

At the early stage of admission, because of high fever, water loss, and insufficient intake, patients with severe COVID-19 had insufficient capacity, low blood pressure, and high blood viscosity. Multiple organ failure caused by diffuse microvascular damage is an important cause of death in critical patients with COVID-19 [4,17]. A multicenter retrospective study of 1099 patients with COVID-19 showed that the incidence of DIC (2.9% vs. 0.1%) and the mortality (8.1% vs. 0.1%) were significantly higher than those of non-ICU patients [2]. A retrospective analysis of 21 patients with COVID-19 revealed that 71.4% of the dead
patients had DIC, while the incidence of DIC in survival patients was only 0.6% [4]. Therefore, coagulation disorder and DIC are the vital causes of death in critical type with COVID-19.

COVID-19 is a systemic infectious disease mainly caused by SARS-CoV-2. The functional receptors for this newly emerged coronavirus can mediate SARS-CoV-2 S-mediated entry into cells, such as ACE2 [18–21]. The immune system in patients with COVID-19 is over activated, thereby releasing a large number of inflammatory mediators and promoting platelet aggregation [22]. After SARS-CoV-2 infection, the immune response mediates the damage of hematopoiesis system, cell inflammatory damage, microvascular system damage, abnormal activation of coagulation system, inhibition of fibrinolysis and

Table 2
Laboratory findings of patients with COVID-19 on admission.

| Characteristics | Total (n = 117) | Non-CAC (n = 56) | CAC (n = 61) | P value |
|-----------------|----------------|------------------|--------------|---------|
| **Inflammatory parameters** |               |                  |              |         |
| PCT (ng/ml), median (IQR) | 0.06 (0.04, 0.08) | 0.05 (0.04, 0.07) | 0.06 (0.04, 0.09) | 0.042 |
| CRP (mg/dl), median (IQR) | 22.7 (9.0, 44.7) | 13.9 (7.8, 28.2) | 32.0 (16.2, 57.3) | < 0.001 |
| IL-6 (pg/ml), median (IQR) | 19.8 (12.2, 43.1) | 19.1 (6.4, 27.0) | 22.2 (16.0, 52.1) | 0.018 |
| **Blood routine tests** |               |                  |              |         |
| WBC (1 × 109/L), median (IQR) | 4.7 (3.8, 5.9) | 4.8 ± 1.5 | 5.3 ± 2.1 | 0.11 |
| HGB (g/L), mean ± SD | 136.9 ± 15.4 | 139.0 ± 14.4 | 135.0 ± 16.2 | 0.16 |
| Neutrophils (1 × 109/L), median (IQR) | 3.0 (2.2, 3.9) | 2.6 (2.0, 3.6) | 3.2 (2.4, 4.4) | 0.014 |
| Lymphocyte (1 × 109/L), median (IQR) | 1.2 (0.9, 1.5) | 1.2 (1.0, 1.6) | 1.1 (0.8, 1.4) | 0.012 |
| Monocytes, median (IQR) | 0.4 (0.3, 0.6) | 0.5 (0.4, 0.5) | 0.4 (0.3, 0.6) | 0.17 |
| Platelets (1 × 109/L), mean ± SD | 177.0 ± 60.7 | 187.6 ± 62.0 | 167.1 ± 58.4 | 0.069 |
| **Biochemical parameters** |               |                  |              |         |
| PCT, procalcitonin; CRP, C-reaction protein; WBC, white blood cell; RBC, red blood cell; HGB, hemoglobin; NLR, neutrophil/lymphocyte ratio; PLT, platelets; PLR, platelets/lymphocyte ratio; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; PT, prothrombin time; APTT, activated partial thromboplastin time; FIB, fibrinogen. ISTH: International Society of Thrombosis & Haemostasis.

Table 3
Complications and outcomes of patients with COVID-19.

| Outcomes, N (%) | Total (n = 117) | Non-CAC (n = 56) | CAC (n = 61) | P value |
|-----------------|----------------|------------------|--------------|---------|
| The primary end points |               |                  |              |         |
| Admission to ICU | 35 (29.9) | 9 (16.1) | 26 (42.6) | 0.002 |
| Mechanical ventilation |                 |                  |              |         |
| Invasive ventilation | 14 (12.0) | 1 (1.8) | 13 (21.3) | 0.001 |
| Noninvasive ventilation | 44 (37.6) | 12 (21.4) | 32 (52.5) | 0.001 |
| The secondary end point |               |                  |              |         |
| Discharge from admission |                 |                  |              |         |
| 14 days | 37 (31.6) | 27 (48.2) | 10 (16.4) | < 0.001 |
| 21 days | 70 (59.8) | 42 (75.0) | 28 (45.9) | 0.001 |
| 28 days | 94 (80.3) | 50 (89.3) | 44 (72.1) | 0.022 |
| AHI | 54 (46.2) | 16 (28.6) | 38 (62.3) | < 0.001 |
| ARDS | 22 (18.8) | 5 (8.9) | 17 (27.9) | 0.009 |
| Shock | 8 (6.8) | 1 (1.8) | 7 (11.5) | 0.063 |
| AKI | 3 (2.6) | 0 (0.0) | 3 (4.9) | 0.25 |
| ARI | 5 (4.3) | 1 (1.8) | 4 (6.6) | 0.37 |
| LOS (days), median (IQR) | 17 (14, 27) | 15 (13, 22) | 23 (16, 30) | < 0.001 |
| Mortality | 2 (1.7) | 0 (0.0) | 2 (3.3) | 0.25 |

Abbreviations: ICU: intensive care unit; ACD, acute cardiac dysfunction; AKI, acute kidney injury; AHI, acute hepatic injury; ARDS, acute respiratory distress syndrome; ALI, acute lung injury; MV, mechanical ventilation; ICU, intensive care unit; LOS, length of stay; IQR: interquartile range.

[18–21]. The immune system in patients with COVID-19 is over activated, thereby releasing a large number of inflammatory mediators and promoting platelet aggregation [22]. After SARS-CoV-2 infection, the immune response mediates the damage of hematopoiesis system, cell inflammatory damage, microvascular system damage, abnormal activation of coagulation system, inhibition of fibrinolysis and
anticoagulation system, which eventually leads to coagulation dysfunction. Thus, COVID-19 related coagulopathy is an early manifestation in the evolution of DIC, showing a dynamic change process.

The molecular markers of coagulation and fibrinolysis can reflect the pathological process of pre-DIC, including sTM, TAT, and plasminogen activator inhibitor–1 (PAI-1), but they are detected with difficulty in fever clinic worldwide, thus it is impossible to early predict the activation of coagulation in many cases. The criterion of sepsis associated coagulation disorder (SAC) formulated in the United States only uses two indexes, i.e. international standardized ratio (INR) and platelet count. SAC criterion is optional and convenient in the emergency or basic hospitals [23], nevertheless, INR and platelets did not show obvious alterations at the early stage of patients with COVID-19 in our study. Thus, it was not suitable for the coagulation abnormality induced by COVID-19. The platelet counts in most patients with COVID-19 were in normal range or slightly increased, but the mean level was controversial between severe and no-severe patients [6,24]. Other patients, especially severe and dead patients, the platelet counts might be reduced [6,24]. Recently, 50% of patients with COVID-19 reportedly increased D-dimer contents, and FDP and D-dimer levels were significantly elevated in severe and dead patients [23]. However, fibrinogen was markedly increased at the early stage of mild patients with COVID-19, and decreased at the late stage of severe patients [3].

The coagulation dysfunction or DIC induced by COVID-19 are a dynamic process, so the sensitivity and specificity of single index for DIC diagnosis are not good. Rational use of DIC integration system is conducive to the early diagnosis, prevention, and treatment of disease. Previous studies have shown that the ISTH criterion can diagnose septic DIC within a certain range. COVID-19 is a kind of sepsis, a viral sepsis. Therefore, it may have the characteristics of sepsis. In our clinical observation, we used ISTH system and ISTH score more than or equal to 2 points to identify the coagulation dysfunction. The results showed that patients with ISTH score (≥ 2) had a less proportion of the discharges of 14 days, 21 days and 28 days from admission. Multiple logistic regression analysis indicated that the proportion of patients with ISTH score ≥ 2 entering ICU was 4.07 times of those with ISTH score < 2, and the proportion of patients with mechanical ventilation was 5.54 times of patients with ISTH score < 2. Therefore, using the COVID-19 associated coagulopathy scoring system can identify potential critical COVID-19 patients at early.

4.1. Limitations

Our study has several limitations. Firstly, 32 cases had incomplete documentation of laboratory testing on admission within 24 h. Secondly, because 10 patients (8 critical ill patients, 2 general patients) remained in the hospital and the outcomes were unknown at the time of data cutoff, we censored the data regarding their clinical outcomes as of the time of our analysis. Thirdly, the current study is a retrospective study with limited cases, it needs to be further confirmed by large sample cohort study.

5. Conclusions

Until now, no specific indicators of patients in early admission have been recommended for COVID-19. Currently, the approach to such disease is to control the source of infection and use of personal protection precaution to reduce the risk of transmission. Early diagnosis and identifying the patients who may become critical on the day of admission are of importance for the treatment of COVID-19. Our study demonstrated that the presence of coagulopathy identifies a group of patients with COVID-19 at higher risk for admission to ICU, and mechanical ventilation as well as discharges of 14 days, 21 days and 28 days from admission. ISTH score more than or equal to 2 points is a vital indicator of patients with COVID-19 on early admission.

Table 4
Risk factors associated with admission to ICU.

| Variable | Univariable | Multivariable |
|----------|-------------|---------------|
|          | OR (95% CI) | P value       | OR (95% CI) | P value       |
| Age > 60 | 4.92 (2.11, 11.48) | <0.001        | 5.21 (1.96, 13.89) | 0.001 |
| Male     | 4.53 (1.84, 11.17)  | 0.001        | 6.47 (2.22, 18.91) | <0.001 |
| ISTH score ≥ 2 | 3.88 (1.62, 9.31) | 0.0002       | 4.07 (1.47, 11.25) | 0.007 |
| Platelet counts (10^9/L) | 0.99 (0.98, 1)  | 0.035        | N/A           |
| Neutrophil/lymphocyte ratio | 1.25 (1.07, 1.47) | 0.005        | N/A           |
| Alanine aminotransferase (U/L) | 1.01 (0.99, 1.03) | 0.34        | N/A           |
| Aspartate transaminase (U/L) | 1.05 (1.02, 1.08) | 0.001        | N/A           |
| Creatinine > 133 μmol/L | 16.76 (1.90, 145.15) | 0.011        | N/A           |
| Comorbidities | 2.79 (1.21, 6.47) | 0.017        | N/A           |
| APACHE II score | 1.28 (1.1, 1.48) | 0.001        | N/A           |

Table 5
Risk factors associated with the use of mechanical ventilation.

| Variable | Univariable | Multivariable |
|----------|-------------|---------------|
|          | OR (95% CI) | P value       | OR (95% CI) | P value       |
| Age > 60 | 4.58 (2.06, 10.17) | <0.001        | 4.94 (1.84, 13.27) | 0.002 |
| Male     | 5.19 (2.26, 11.89)  | <0.001        | 8.43 (2.86, 24.85) | <0.001 |
| ISTH score ≥ 2 | 4.62 (2.05, 10.42) | <0.001        | 5.54 (2.01, 15.28) | 0.001 |
| Platelet counts (10^9/L) | 0.99 (0.98, 1)  | 0.004        | N/A           |
| Neutrophil/lymphocyte ratio | 1.27 (1.07, 1.5)  | 0.007        | N/A           |
| Alanine aminotransferase (U/L) | 1.02 (1.04) | 0.082        | N/A           |
| Aspartate transaminase (U/L) | 1.05 (1.02, 1.08) | 0.001        | N/A           |
| Comorbidities | 2.42 (1.08, 5.43) | 0.032        | N/A           |
| APACHE II score | 1.24 (1.09, 1.43) | 0.002        | N/A           |
implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review, J. Am. Coll. Cardiol. 75 (23) (Jun 16 2020) 2950–2973, https://doi.org/10.1016/j.jacc.2020.04.031.

[7] World Health Organization, Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, https://www.who.int/docs/default-source/coronaviruses/coronavirus-clinical-management-of-novel-cov.pdf?sfvrsn=1 (January 28, 2020) (opens in new tab).

[8] John A Kellum, Norbert Lameire, Peter Aupin, Rashad S. Bar soum, Emmanuel A Burdman, Stuart L Goldstein, Charles A Herzog, Michael Joannidis, Andreas Kribben, Andrew S Levey, Alison M MacLeod, Ravindra L Mehta, Patrick T Murray, Saraladevi Naicker, Steven M Opal, Franz Schaefer, Miet Schetz, Shigehiko Uchino, Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO Clinical Practice Guidance for Acute Kidney Injury. Kidney International Supplements 2 (1) (2013) 1–138.

[9] Haruhiko Kobashi, Junichi Toshimori, Kazuhide Yamamoto, Seiji-associated liver injury: incidence, classification and the clinical significance, Hepatol Res. 43 (3) (2013) 259–266, https://doi.org/10.1111/j.1872-034X.2012.01069.x.

[10] Yu-dong Yin, Richard G Wunderink, MERIS, SARS and other coronaviruses as causes of pneumonia, Respirology 23 (2) (2018) 130–137, https://doi.org/10.1111/resp.13596.

[11] Alaa Badawi, Seung Gwan Ryo, Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis, Int. J. Infect. Dis. 66 (2016) 129–133, https://doi.org/10.1016/j.ijid.2016.06.015.

[12] Maximilian Ackermann, Stijn E Verleden, Mark Kuehnel, Axel Haverich, Tobias Welter, Florian Laenger, Arno Vanstapel, Christopher Werlein, Helge Stark, Alexandar Tzanov, William W Li, Vincent W Li, Steven J Meintjies, Danny Jonigk, Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19, N. Engl. J. Med. 383 (2020) 120–128, https://doi.org/10.1056/NEJMoa2002032.

[13] Chao-lin Huang, Ye-ming Wang, Xing-wang Li, Li-li Ren, Jian-ping Zhao, Yi Hu, Li Zhang, Guohui Fan, Ji-yang Xu, Xiao-ying Gu, Zhen-sheng Chen, Ying Tu, Jian-an Xian, Yuan Wei, Wen-jun Wu, Xue-lei Xie, Wen Yin, Mi Liu, Yan Xiao, Hong Gao, Li Guo, Jun-xing Xie, Guang-fa Wang, Rong-meng Jiang, Zhan-cheng Gao, Qi Jin, Jian-wei Bao, Bin Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Clin. Infect. Dis. 6 (4) (2006) e1–e5, https://doi.org/10.1086/504943.

[14] Vincent C C Cheng, Susanna K P Lau, Patrick CYW Woo, Yung Yuen, Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infections, Clin. Microbiol. Rev. 20 (4) (2007) 660–694, https://doi.org/10.1128/CMR.00032-07.

[15] Rea Andermatt, Annelies S Zinkernagel, Mandeep R Mehra, Reto A Schuepbach, Frank Ruschitzka, Holger Moch, Endothelial Cell Infection and Endotheliitis in COVID-19, lancet 395 (10234) (2020) 1417–1418, https://doi.org/10.1016/S0140-6736(20)30937-5.

[16] Emma Lefrançais, Guadalupe Ortiz-Muñoz, Axelle Caudrillier, Beñat Mallavia, Marco Witkowski, Ulf Landmesser, Ursula Rauch, Tissue factor as a link between mechanisms and potential therapeutic target, J. Thromb. Haemost. (2020), https://doi.org/10.1111/JTH.14810.

[17] Alaa Badawi, Seung Gwan Ryo, Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis, Int. J. Infect. Dis. 66 (2016) 129–133, https://doi.org/10.1016/j.ijid.2016.06.015.

[18] Alaa Badawi, Seung Gwan Ryo, Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis, Int. J. Infect. Dis. 66 (2016) 129–133, https://doi.org/10.1016/j.ijid.2016.06.015.

[19] Emmanuel J Favaloro, Jawed Fareed, Joseph A Caprini, Alfonso J Tafur, John Morris, Mohammad Madjid, Yutao Guo, Liang V Tang, Yu Hu, Jay Giri, Mary Cushman, William J Liu, Min Zhao, Qin Ning, Clinical and immunologic features in severe and moderate COVID-19 pneumonia and thrombotic syndromes, N. Engl. J. Med. 383 (2) (2020) 120–128, https://doi.org/10.1056/NEJMoa2002032.

[20] Marco Witkowski, Ulf Landmesser, Ursula Rauch, Tissue factor as a link between mechanisms and potential therapeutic target, J. Thromb. Haemost. (2020), https://doi.org/10.1111/JTH.14810.

[21] Marco Witkowski, Ulf Landmesser, Ursula Rauch, Tissue factor as a link between mechanisms and potential therapeutic target, J. Thromb. Haemost. (2020), https://doi.org/10.1111/JTH.14810.